CRBP has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
CRBP has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Corbus Pharmaceuticals Holdings's EBITDA per Share for the three months ended in Dec. 2024 was $-0.77.
During the past 3 years, the average EBITDA Per Share Growth Rate was 36.10% per year. During the past 5 years, the average EBITDA Per Share Growth Rate was 38.50% per year. During the past 10 years, the average EBITDA Per Share Growth Rate was 1.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 12 years, the highest 3-Year average EBITDA Per Share Growth Rate of Corbus Pharmaceuticals Holdings was 41.60% per year. The lowest was -181.90% per year. And the median was -34.00% per year.
For the Biotechnology subindustry, Corbus Pharmaceuticals Holdings's 5-Year EBITDA Growth Rate, along with its competitors' market caps and 5-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Corbus Pharmaceuticals Holdings's 5-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Corbus Pharmaceuticals Holdings's 5-Year EBITDA Growth Rate falls into.
This is the 5-year average growth rate of EBITDA per Share. The growth rate is calculated with least square regression.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
Corbus Pharmaceuticals Holdings (NAS:CRBP) 5-Year EBITDA Growth Rate Explanation
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
5-Year EBITDA Growth Rate gives an overview of the company's growth in operating profitability and is an important factor used in calculating Peter Lynch Fair Value.
Thank you for viewing the detailed overview of Corbus Pharmaceuticals Holdings's 5-Year EBITDA Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.
Yuval Cohen | director, officer: Chief Executive Officer | C/O CORBUS PHARMACEUTICALS HOLDINGS, INC, 100 RIVER RIDGE DRIVE, NORWOOD MA 02062 |
Sean F. Moran | officer: Chief Financial Officer | 10220-L OLD COLUMBIA ROAD, COLUMBIA MD 21046 |
Yong Ben | director | 500 RIVER RIDGE DRIVE, NORWOOD MA 02062 |
Anne Altmeyer | director | 500 RIVER RIDGE DRIVE, NORWOOD MA 02062 |
Craig Stuart Millian | officer: Chief Commercial Officer | C/O CORBUS PHARMACEUTICALS HOLDINGS, INC, 100 RIVER RIDGE DRIVE, NORWOOD MA 02062 |
Rachael Louise Brake | officer: Chief Scientific Officer | 21 MANCHESTER PLACE, NATICK MA 01760 |
George Golumbeski | director | C/O CELGENE CORP., 86 MORRIS AVENUE, SUMMIT NJ 07901 |
Peter Salzmann | director | 320 W 37TH STREET, 3RD FLOOR, NEW YORK NY 10016 |
Barbara White | officer: Chief Medical Officer | C/O CORBUS PHARMACEUTICALS HOLDINGS, INC, 100 RIVER RIDGE DRIVE, NORWOOD MA 02062 |
Robert Paul Discordia | officer: Chief Operating Officer | C/O CORBUS PHARMACEUTICALS HOLDINGS, INC, 500 RIVER RIDGE DRIVE, NORWOOD MA 02062 |
Rachelle Suzanne Jacques | director | C/O CORBUS PHARMACEUTICALS HOLDINGS, INC, 100 RIVER RIDGE DRIVE, NORWOOD MA 02062 |
David P Hochman | director | 15 WESTON HILL RD., RIVERSIDE CT 06878 |
John Kenneth Jenkins | director | C/O CORBUS PHARMACEUTICALS HOLDINGS, INC, 100 RIVER RIDGE DRIVE, NORWOOD MA 02062 |
Paris Panayiotopoulos | director | ARIAD PHARMACEUTICALS, INC., 26 LANDSDOWNE STREET, CAMBRIDGE MA 02139 |
Avery W Catlin | director | 241 CENTRAL STREET, HINGHAM MA 02043 |
From GuruFocus
By GuruFocus News • 10-15-2024
By Marketwired • 05-30-2024
By Marketwired • 01-28-2025
By Marketwired • 09-26-2024
By Marketwired • 11-12-2024
By Marketwired • 08-20-2024
By Marketwired • 02-11-2025
By Marketwired • 05-01-2024
By Marketwired • 07-30-2024
By GuruFocus News • 02-15-2025
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.